TrialBlood advances2024

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.

Itaru Matsumura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.